KRAS and non-small cell lung carcinoma: Given that KRAS mutations are prevalent in almost 30% of non-small cell lung cancer (NSCLC) patients [2], we chose a KrasG12D-driven spontaneous lung cancer murine model to elucidate the detailed mechanism by which DDX3X regulates lung cancer progression, which might be also extended to KRAS wildtype lung cancers.